Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
Adding immunotherapy to chemotherapy plus bevacizumab shows promising benefit in survival for non-epitheliod mesothelioma patients, but not across the board
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
